Search research articles
Contact Us
Filters
Showing results (21-30 of 42) with videos related to
Page
of 5
Sort By:
Kidney International
|
December 14, 2012
The synthetic triterpenoid, RTA 405, increases the glomerular filtration rate and reduces angiotensin II-induced contraction of glomerular mesangial cells
Yanfeng Ding, Rhesa D Stidham, Ron Bumeister, et al.
Plos One
|
November 27, 2024
Correction: Triterpenoid Dihydro-CDDO-Trifluoroethyl Amide Protects against Maladaptive Cardiac Remodeling and Dysfunction in Mice: A Critical Role of Nrf2
Yifan Xing, Ting Niu, Wenjuan Wang, et al.
Plos One
|
October 3, 2012
Triterpenoid dihydro-CDDO-trifluoroethyl amide protects against maladaptive cardiac remodeling and dysfunction in mice: a critical role of Nrf2
Yifan Xing, Ting Niu, Wenjuan Wang, et al.
Cardiorenal Medicine
|
June 7, 2019
Effects of Bardoxolone Methyl on Magnesium in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease
Dana V Rizk, Arnold L Silva, Pablo E Pergola, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology
|
August 22, 2019
Bardoxolone methyl analog attenuates proteinuria-induced tubular damage by modulating mitochondrial function
Hajime Nagasu, Yuji Sogawa, Kengo Kidokoro, et al.
Journal of Cardiac Failure
|
October 14, 2014
Risk factors for heart failure in patients with type 2 diabetes mellitus and stage 4 chronic kidney disease treated with bardoxolone methyl
Melanie P Chin, Danielle Wrolstad, George L Bakris, et al.
FEBS Letters
|
May 13, 2014
Targeting Nrf2 by dihydro-CDDO-trifluoroethyl amide enhances autophagic clearance and viability of β-cells in a setting of oxidative stress
Wenjuan Li, Weiwei Wu, Haibo Song, et al.
The New England Journal of Medicine
|
June 25, 2011
Bardoxolone methyl and kidney function in CKD with type 2 diabetes
Pablo E Pergola, Philip Raskin, Robert D Toto, et al.
American Journal of Nephrology
|
June 7, 2014
Mechanisms contributing to adverse cardiovascular events in patients with type 2 diabetes mellitus and stage 4 chronic kidney disease treated with bardoxolone methyl
Melanie P Chin, Scott A Reisman, George L Bakris, et al.
Clinical and Translational Science
|
August 30, 2020
Effects of Bardoxolone Methyl on Hepatic Enzymes in Patients with Type 2 Diabetes Mellitus and Stage 4 CKD
James H Lewis, Michel Jadoul, Geoffrey A Block, et al.
Page
of 5
Search research articles
Search
Showing results (21-30 of 42) with videos related to
Sort By:
Page
of 5
Kidney International
|
December 14, 2012
The synthetic triterpenoid, RTA 405, increases the glomerular filtration rate and reduces angiotensin II-induced contraction of glomerular mesangial cells
Yanfeng Ding, Rhesa D Stidham, Ron Bumeister, et al.
Plos One
|
November 27, 2024
Correction: Triterpenoid Dihydro-CDDO-Trifluoroethyl Amide Protects against Maladaptive Cardiac Remodeling and Dysfunction in Mice: A Critical Role of Nrf2
Yifan Xing, Ting Niu, Wenjuan Wang, et al.
Plos One
|
October 3, 2012
Triterpenoid dihydro-CDDO-trifluoroethyl amide protects against maladaptive cardiac remodeling and dysfunction in mice: a critical role of Nrf2
Yifan Xing, Ting Niu, Wenjuan Wang, et al.
Cardiorenal Medicine
|
June 7, 2019
Effects of Bardoxolone Methyl on Magnesium in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease
Dana V Rizk, Arnold L Silva, Pablo E Pergola, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology
|
August 22, 2019
Bardoxolone methyl analog attenuates proteinuria-induced tubular damage by modulating mitochondrial function
Hajime Nagasu, Yuji Sogawa, Kengo Kidokoro, et al.
Journal of Cardiac Failure
|
October 14, 2014
Risk factors for heart failure in patients with type 2 diabetes mellitus and stage 4 chronic kidney disease treated with bardoxolone methyl
Melanie P Chin, Danielle Wrolstad, George L Bakris, et al.
FEBS Letters
|
May 13, 2014
Targeting Nrf2 by dihydro-CDDO-trifluoroethyl amide enhances autophagic clearance and viability of β-cells in a setting of oxidative stress
Wenjuan Li, Weiwei Wu, Haibo Song, et al.
The New England Journal of Medicine
|
June 25, 2011
Bardoxolone methyl and kidney function in CKD with type 2 diabetes
Pablo E Pergola, Philip Raskin, Robert D Toto, et al.
American Journal of Nephrology
|
June 7, 2014
Mechanisms contributing to adverse cardiovascular events in patients with type 2 diabetes mellitus and stage 4 chronic kidney disease treated with bardoxolone methyl
Melanie P Chin, Scott A Reisman, George L Bakris, et al.
Clinical and Translational Science
|
August 30, 2020
Effects of Bardoxolone Methyl on Hepatic Enzymes in Patients with Type 2 Diabetes Mellitus and Stage 4 CKD
James H Lewis, Michel Jadoul, Geoffrey A Block, et al.
Page
of 5